Table 3.
Antibody-drug conjugates and radiolabeled antibodies in clinical development for the treatment of aggressive NHL. [CR: complete response; CRu: unconfirmed CR; DLBCL: diffuse large B-cell lymphoma; HDT-ASCT: high-dose therapy/autologous stem cell transplantation; mAb: monoclonal antibody; MOA: mechanism of action; mPFS: median progression-free survival; NHL: non-Hodgkin lymphoma; ORR: overall response rate; OS: overall survival; PFS: progression-free survival; R: rituximab; R-CHOP: cyclophosphamide, doxorubicin, vincristine, prednisolone plus rituximab; RIT: radioimmunotherapy; R/R: relapsed or refractory.]
| Drug | MOA (target) | Eligibility (and design) | Phase | Randomized | Results |
|---|---|---|---|---|---|
| I-131 tositumomab [96] | Anti-CD20 radioimmunotherapy | Previously untreated DLBCL (with R-CHOP) | No | 1-year PFS rate: 75%; 1-year OS rate: 83% | |
| Inotuzumab ozogamicin (CMC-544) [93] | CD22 targeted cytotoxic immunoconjugate | R/R CD22+ and CD20+ NHL (with R) | I | No | ORR: 80%; 1-year PFS rate: 89% |
| Inotuzumab ozogamicin (CMC-544) [94] | CD22 targeted cytotoxic immunoconjugate | R/R CD22+ and CD20+ DLBCL prior to HDT-ASCT (with R) | No | ORR: 21% | |
| 90Y-epratuzumab tetraxetan [92] | Radiolabeled humanized anti-CD22 mAb | R/R NHL | I/II | Dose-finding | ORR: 62%; CR/CRu: 48%; mPFS: 9.5 months |
| 90Y-epratuzumab tetraxetan [97] | Radiolabeled humanized anti-CD22 mAb | Consolidation after first-line R-CHOP in DLBCL | II | No | Improved remission status 6 weeks after RIT: 30.7% |
| Brentuximab vedotin (SGN-35) [104] | Antitubulin monomethyl auristatin E (MMAE) anti-CD30 mAb conjugate | R/R lymphoma | I | ORR: 46%; CR: 29% |